GENMAB (GMAB) Company Report

Analyst Coverage

Research analysts who have asked questions during GENMAB earnings calls.

Asthika Goonewardene

Truist Securities

4 questions for GMAB

Also covers: ALLO, AUTL, BNTX +9 more

Yaron Werber

TD Cowen

4 questions for GMAB

Also covers: ALEC, AMGN, ARGX +14 more

Jonathan Chang

Leerink Partners

3 questions for GMAB

Also covers: ADAP, IMCR, KPTI +10 more

Matthew Phipps

William Blair

3 questions for GMAB

Also covers: ABBV, AGEN, AMGN +8 more

Michael Schmidt

Guggenheim Securities

3 questions for GMAB

Also covers: ADAP, ADCT, ARVN +19 more

Rajan Sharma

Goldman Sachs Group, Inc.

3 questions for GMAB

Also covers: ARGX, AUTL, AZN +6 more

Qize Ding

Redburn Atlantic

2 questions for GMAB

Vikram Purohit

Morgan Stanley

2 questions for GMAB

Also covers: ABSI, ARGX, ARQT +11 more

Xian Deng

Berenberg

2 questions for GMAB

Also covers: ARGX, GLPG

Emily Field

Barclays

1 question for GMAB

Also covers: AZN, GSK, NVO +2 more

Etzer Darout

BMO Capital Markets

1 question for GMAB

Also covers: ARVN, CTMX, EXEL +5 more

Peter Verdult

Citigroup Inc.

1 question for GMAB

Also covers: AZN, EVO, GRFS +4 more

Sachin Jain

Bank of America

1 question for GMAB

Also covers: AZN, GSK, NVO +2 more

Suzanne van Voorthuizen

Kempen & Co

1 question for GMAB

Also covers: ARGX, BNTX, HOOK +3 more

Yifeng Liu

HSBC

1 question for GMAB

Also covers: BNTX

Latest news

Recent press releases and 8-K filings for GMAB.

Genmab Announces 2025 Net Sales for DARZALEX®

GMAB

Earnings

Genmab A/S announced that worldwide net trade sales of DARZALEX® (daratumumab) in 2025 totaled USD 14,351 million.
These sales were comprised of USD 8,266 million from the U.S. and USD 6,085 million from the rest of the world.
Genmab receives royalties on these worldwide net sales from Johnson & Johnson.

Jan 21, 2026, 12:02 PM

6-K

Genmab Announces Topline Phase 3 Results for Epcoritamab in DLBCL

GMAB

Product Launch

New Projects/Investments

Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab monotherapy in patients with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).
The trial demonstrated a statistically significant improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92]), along with improvements in complete response rate, duration of response, and time to next treatment.
This marks the first Phase 3 study to show PFS improvement for a CD3xCD20 T-cell engaging bispecific monotherapy in relapsed or refractory DLBCL.
However, overall survival (OS) (HR: 0.96 [95% CI 0.77 to 1.20]) did not reach statistical significance in the study.
Genmab and AbbVie will engage global regulatory authorities to discuss next steps for epcoritamab, which is already approved in over 65 countries for certain lymphoma indications.

Jan 16, 2026, 6:41 PM

6-K

Genmab Announces Positive Topline Results for Epcoritamab Phase 3 Trial

GMAB

Product Launch

New Projects/Investments

Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
The trial demonstrated a statistically significant improvement in progression-free survival (PFS) with epcoritamab monotherapy (HR: 0.74 [95% CI 0.60 to 0.92]).
This marks the first Phase 3 study to show improved PFS for a CD3xCD20 T-cell engaging bispecific monotherapy in this patient population.
Genmab and AbbVie will engage global regulatory authorities to discuss next steps for epcoritamab based on these results.

Jan 16, 2026, 6:31 PM

Press Release

Genmab Announces Positive Topline Results from EPCORE DLBCL-1 Trial

GMAB

Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The trial demonstrated a statistically significant improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92]), making it the first Phase 3 study to show such improvement in this patient population with a CD3xCD20 T-cell engaging bispecific monotherapy.
Genmab and AbbVie will engage global regulatory authorities to discuss the next steps for epcoritamab based on these results.

Jan 16, 2026, 6:30 PM

Press Release

Genmab CEO Discusses 2026 Strategy and Late-Stage Pipeline at J.P. Morgan Conference

GMAB

M&A

New Projects/Investments

Guidance Update

Genmab is positioned for sustainable long-term growth with a diversified revenue base and a powerful late-stage pipeline, including nine medicines on the market after the acquisition of Merus.
2026 is anticipated to be a transformational year with up to six potential registrational data readouts for three high-impact late-stage programs: Epkinly, Rina-S, and petosemtamab, setting the stage for multiple important product launches and line extensions in 2027.
Epkinly demonstrated phase III superiority in follicular lymphoma and has three phase III trials in diffuse large B-cell lymphoma with data expected in 2026, aiming to significantly increase its addressable patient population.
Rina-S is designed to broaden eligibility in folate receptor alpha-targeted treatment, with encouraging anti-tumor activity in ovarian and endometrial cancers and ongoing phase III trials.
Petosemtamab, acquired through Merus, shows compelling data in head and neck cancer, with top-line data from phase III trials expected in the second half of 2026.

Jan 13, 2026, 11:45 PM

Transcript

Genmab Outlines 2026 Catalysts and Long-Term Growth Strategy

GMAB

New Projects/Investments

M&A

Revenue Acceleration/Inflection

Genmab begins 2026 with a diversified revenue base from nine marketed medicines and a late-stage portfolio positioned for sustainable long-term growth into the 2030s.
The company anticipates a catalyst-rich 2026 with up to six potential registrational data readouts for key assets: Epkinly, Rina S, and Petosemtamab, which could lead to multiple product launches and line extensions starting in 2027.
Epkinly demonstrated phase three superiority over standard of care in follicular lymphoma and is expected to have three phase three data readouts in diffuse large B-cell lymphoma in 2026, aiming to significantly expand its addressable patient population.
Petosemtamab, acquired through Merus, achieved a 63% response rate in combination with Pembro in first-line head and neck cancer, more than triple the standard of care, with top-line phase three data anticipated in the second half of 2026.
Genmab is financially profitable and is strategically transforming into a fully integrated biotech, focusing on operational efficiencies and disciplined investment in high-priority programs.

Jan 13, 2026, 11:45 PM

Transcript

Genmab Outlines 2026 as Pivotal Year with Key Clinical Data Readouts and Future Product Launches

GMAB

New Projects/Investments

Guidance Update

Revenue Acceleration/Inflection

Genmab is transitioning from a royalty-based company to a fully integrated, innovation-driven biotech with a diversified revenue base from nine marketed medicines, including co-owned Epkinly and Tivdak.
2026 is expected to be a "catalyst-rich year" with up to six potential registrational data readouts for three high-impact late-stage assets: Epkinly, Rina S, and petosemtamab, which could lead to commercial launches starting in 2027.
Rina S has an upgraded peak sales estimate of $2 billion , with phase 2 pivotal data anticipated in H2 2026. Petosemtamab demonstrated a 63% response rate in first-line head and neck cancer in combination with Pembro, with phase 3 top-line data also expected in H2 2026.
The company is financially profitable and focused on driving operational efficiencies and savings, particularly in phase three trials, to free up capital for expansion opportunities.

Jan 13, 2026, 11:45 PM

Transcript

Genmab discontinues acasunlimab clinical development

GMAB

New Projects/Investments

Guidance Update

Genmab A/S has decided to discontinue the clinical development of acasunlimab following a portfolio review.
This decision reflects the company's prioritization of higher-impact opportunities within its late-stage pipeline and an increasingly competitive landscape.
Genmab will now concentrate resources on programs such as EPKINLY® (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S®).
The company confirmed that this decision does not impact its full-year 2025 financial guidance.

Dec 29, 2025, 1:27 PM

6-K

Genmab Discontinues Acausunlimab Clinical Development

GMAB

New Projects/Investments

Guidance Update

Genmab announced the discontinuation of clinical development for acasunlimab following a portfolio review.
This decision reflects a strategic focus on higher-impact opportunities within its late-stage pipeline, including EPKINLY® (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S®), and the evolving competitive landscape.
The company confirmed that this discontinuation does not impact Genmab’s full-year 2025 financial guidance.

Dec 29, 2025, 1:12 PM

Press Release

Genmab Completes Tender Offer for Merus N.V. Shares

GMAB

M&A

New Projects/Investments

Takeover Bid

Genmab A/S has completed its tender offer to acquire common shares of Merus N.V. for $97 per common share in cash.
As of December 11, 2025, 94.2% of Merus's issued and outstanding common shares were validly tendered.
The acquisition adds petosemtamab, a late-stage asset, to Genmab's portfolio, with an anticipated launch in 2027.
Genmab expects the transaction to be accretive to EBITDA by the end of 2029, with petosemtamab projected to achieve at least one-billion-dollar annual sales potential by 2029.
A subsequent offering period for additional Merus shares at $97.00 per share commenced on December 12, 2025, and will expire on December 29, 2025.